Prevencio
- Company typePrivate
- Founded2013
- HeadquartersKirkland, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Prevencio firmographics
Firmographics- Name
- Prevencio
- Legal name
- Prevencio Inc.
- Website
- https://prevenciomed.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Prevencio industry classification
Industry- Product category
- Cardiovascular Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
Keywords
Where Prevencio is headquartered
LocationHeadquarters
- HQ city
- Kirkland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Prevencio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- AI-Powered Blood Diagnostic Tests: Prevencio generates revenue through the sale of its HART family of AI-powered multi-protein blood tests for cardiovascular disease diagnosis and risk prediction. Tests are ordered by healthcare providers and processed through partner laboratories. Revenue is derived from test kit sales, laboratory processing fees, and reimbursement from Medicare/Medicaid and private insurance.
- Laboratory Services Partnership: Laboratory commercialization partnerships with Atlas Genomics and Complete Omics incorporating Microsoft AI-computing cloud for test processing and delivery.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | HART Test Kits - Medicare National Pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Prevencio product offering
Product offeringCore offering
Prevencio develops and sells the HART family of seven proprietary AI-powered blood diagnostic tests that use multi-proteomic biomarkers combined with clinical variables and machine learning algorithms to predict and diagnose cardiovascular conditions. Tests are ordered by healthcare providers (cardiologists, primary care physicians, hospitals), processed through laboratory partners (Atlas Genomics, Complete Omics), and reimbursed via Medicare, Medicaid, and private insurance using proprietary CPT PLA codes.
Product overview
Prevencio offers a portfolio of seven AI-driven cardiovascular blood tests called HART tests, utilizing multi-proteomic biomarkers, clinical variables, and proprietary machine learning algorithms. The core products include HART CVE (prognostic test for 1-year heart attack/stroke/cardiac death risk), HART CADhs (diagnostic test for obstructive coronary artery disease), HART PAD (peripheral artery disease), HART KD (Kawasaki disease), HART AS (aortic stenosis), HART AKI (acute kidney injury), and HART AMP (amputation risk). Tests are laboratory-developed tests (LDTs) ordered through healthcare providers via a web portal or direct contact, with results delivered through the company's laboratory portal. The tests achieve 85-88% accuracy (AUC), higher than standard-of-care stress tests, CAC scores, genetic risk tests, and clinical risk scores. CPT PLA billing codes were assigned by AMA in 2022, and Medicare pricing was established in 2023.
Differentiator
Problem solved
Functional benefit
Brands
- HART CVE: AI-powered prognostic blood test for predicting 1-4 year risk of heart attack, stroke, or cardiac death (MACE). Assesses four clinically significant blood proteins in a machine learning algorithm.
- HART CADhs
- HART PAD
- HART KD
- HART AS
- HART AKI
Products and services
- HART CVE Prognostic blood test that predicts 1-year risk of heart attack (MI), stroke, or cardiac death (MACE). Assesses four clinically significant blood proteins (NT-proBNP, KIM-1, Osteopontin, TIMP-1) in a machine learning algorithm to calculate a patient-specific risk score with 86% accuracy. For healthcare providers and patients with cardiovascular risk factors or symptoms.
- HART CADhs Diagnostic blood test for detecting obstructive coronary artery disease. Assesses three blood proteins (hsTroponin, Adiponectin, KIM-1) and three clinical variables (age, sex, history of coronary intervention) in a machine learning algorithm to calculate a patient-specific risk score with 86% accuracy. For healthcare providers diagnosing suspected CAD.
- HART PAD Diagnostic blood test for detecting the presence of obstructive peripheral artery disease in patients with and without diabetes mellitus. Algorithmically assesses three biomarkers (KIM-1, Midkine, Angiopoietin-1) and one clinical variable (history of hypertension) with 86% accuracy.
- HART KD Diagnostic blood test for Kawasaki disease, a condition affecting children under 5 years of age. Uses three biomarkers (NT-proBNP, C-reactive protein, T Uptake) in a machine learning model with AUC of 0.92 for accurate diagnosis. Developed in partnership with Seattle Children's Research Institute.
- HART AS Diagnostic blood test for aortic valve stenosis. Predicts with 98% accuracy to exclude severe AS and can diagnose and monitor progression of aortic valvular stenosis. Uses three biomarkers (N-terminal pro-B-type natriuretic peptide, von Willebrand Factor, fetuin-A) and age.
- HART AKI Diagnostic blood test for the risk of acute kidney injury in patients undergoing coronary angiography. Has a negative predictive value of 98% and overall accuracy of 82% (AUC=0.82).
- HART AMP Diagnostic blood test for risk of amputation. Assesses amputation risk in diabetic and non-diabetic patients with overall accuracy of 87% (AUC=0.87).
Quantifiable outcome
- 86% diagnostic accuracy (AUC) for HART CVE and HART CADhs
- +8 more outcomes
Companies that use Prevencio
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Prevencio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Prevencio partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights6 records
Prevencio competitors and assessment
Company assessmentDirect peers
- Cardio Diagnostics Holdings: Public AI-driven cardiovascular diagnostics company offering epigenetic and genetic tests for heart disease risk. Directly comparable as a small-cap AI-cardio diagnostics peer pursuing similar clinical adoption and reimbursement pathways.
- Cleveland HeartLab (Quest Diagnostics): Specialized cardiovascular inflammation and biomarker testing laboratory acquired by Quest Diagnostics. Direct competitor in cardiovascular blood-based diagnostics with established hospital relationships and broader test menu.
- Renalytix: AI-enabled kidney disease diagnostics company with FDA Breakthrough Designation, CPT PLA codes, and Medicare pricing — closely analogous commercialization pathway. Prevencio's former VP of Sales (Missy Martin-Kemp) was previously at Renalytix, reinforcing the comparable commercial profile.
- Singulex: Single-molecule counting immunoassay technology applied to cardiovascular and inflammatory biomarkers. Comparable as a high-sensitivity protein biomarker diagnostics player pursuing cardiovascular risk stratification.
- CardioDx: Historical cardiovascular diagnostics company (Corus CAD test) that validated gene-expression-based blood testing for obstructive CAD. Closely analogous in test category and target use case, even though no longer operating at scale. Prevencio's CCO Missy Martin-Kemp was previously VP of Channel Development at CardioDx.
Emerging players
- SomaLogic: Proteomics-based diagnostics platform measuring thousands of proteins simultaneously. Comparable in proteomics-omics technology approach and cardiovascular/oncology application overlap, though broader in scope.
Broad incumbents
- Abbott Diagnostics: Large in vitro diagnostics incumbent with extensive cardiovascular biomarker menu (troponin, NT-proBNP, Galectin-3) and global commercial reach. Competes indirectly as the established standard-of-care provider with deep hospital relationships.
- Roche Diagnostics: Global IVD leader with cardiac biomarkers (high-sensitivity troponin, NT-proBNP) and Elecsys platform broadly adopted in hospital labs. Represents the entrenched incumbent Prevencio must displace or partner with.
- Myriad Genetics: Specialized diagnostics company with laboratory-developed tests across multiple indications (oncology, mental health, cardiovascular risk). Comparable as a LDT-focused commercial diagnostics business with similar regulatory and reimbursement playbook.
- Exact Sciences: Commercial-stage diagnostics company (Cologuard, Oncotype DX) demonstrating the LDT-plus-CPT-code plus-Medicare-pricing commercialization model at scale. Comparable archetype for novel-diagnostic scaling strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Prevencio social profiles
Digital presencePrevencio compliance and trust
Trust signalCompliance2 records
Prevencio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prevencio leadership team
Management profileNumber of profiles
Profiles13 records
Prevencio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prevencio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prevencio
What does Prevencio do?
Prevencio develops and sells the HART family of seven proprietary AI-powered blood diagnostic tests that use multi-proteomic biomarkers combined with clinical variables and machine learning algorithms to predict and diagnose cardiovascular conditions. Tests are ordered by healthcare providers (cardiologists, primary care physicians, hospitals), processed through laboratory partners (Atlas Genomics, Complete Omics), and reimbursed via Medicare, Medicaid, and private insurance using proprietary CPT PLA codes.
Is Prevencio a public or private company?
Prevencio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Prevencio founded?
Prevencio was founded in 2013. It employs 1 to 10 people.
Where is Prevencio based?
Prevencio is headquartered in Kirkland, United States, in the North America region.
How does Prevencio make money?
Two revenue lines are on record. AI-Powered Blood Diagnostic Tests are the primary driver. The others are laboratory Services Partnership.
Who are Prevencio's main competitors?
Direct peers on record are Cardio Diagnostics Holdings, Cleveland HeartLab (Quest Diagnostics), Renalytix, Singulex and CardioDx. SomaLogic is listed as an emerging player. Broad incumbents are Abbott Diagnostics, Roche Diagnostics, Myriad Genetics and Exact Sciences.
Does Prevencio have an API?
No public API is recorded for Prevencio.
What industry is Prevencio in?
Prevencio's product category is Cardiovascular Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 8071.